EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database

Shahram Attarian iD, Jean-Philippe Camdessanché iD, Andoni Echaniz-Laguna iD, Mariana Ciumas, Cécile Blein, Benjamin Grenier, Guilhem Solé iD

European Journal of Neurology · 2025-01 · 32 (1)

DOI: 10.1111/ene.16518 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Neurology, online erschienen am 04.11.2024. Verfasst von Shahram Attarian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Reference Centre for Neuromuscular Disease and ALS, Timone University Hospital, Aix-Marseille University, CHU Timone, Filnemus, Euro-NMD, Marseille, …. Hauptthemen laut MEDLINE: Hospitalization, Insurance, Health, Myasthenia Gravis, Patient Acuity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Argenx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Few data are available on the course of myasthenia gravis (MG) regarding disease severity and stability over time in real‐world settings. This study used the French National Health Insurance Database (SNDS) to assess markers of disease severity in patients with MG longitudinally.

Methods

All patients with MG‐related claims in the SNDS between 2013 and 2020 were identified. Patients were followed for up to 8 years after the first claim. Intensive care unit (ICU) stays, treatment with intravenous immunoglobulin (IVIg) or plasma exchange (PE), and death were documented throughout the follow‐up period. Standardized mortality rates were estimated, and mortality‐related variables were identified using a Cox model.

Results

In all, 14,459 individuals constituted the full study population, including 6354 incident patients. In the incident population, 2199 (34.6%) were admitted to ICUs at least once, principally during the first year after the index date ( N = 1477; 23.3%). This proportion decreased progressively to reach 3.0% in the seventh year. A total of 2817 patients received IVIg and 432 PE, again principally in the first year. In the full study population, the standardized mortality rate was 1.08 (95% confidence interval [CI] 1.03–1.13), being lower in men (0.95, 95% CI 0.89–1.02) than in women (1.15, 95% CI 1.07–1.23) and in patients aged >65 years (1.06, 95% CI 1.01–1.11) than in younger patients (1.50, 95% CI 1.24–1.76). Male gender, older age and higher comorbidity were independently associated with mortality.

Conclusions

A subgroup of patients with MG require ICU admission and rescue therapy with IVIg or PE, indicative of poor disease control. New therapies are needed to improve disease control and reduce disease burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationInsurance, HealthMyasthenia GravisPatient AcuityTime FactorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedAge FactorsComorbidityDatabases, FactualFranceImmunoglobulins, IntravenousIntensive Care UnitsLongitudinal StudiesPlasma ExchangeRetrospective StudiesRisk FactorsSex FactorsProportional Hazards Models

Stichwörter der Autor:innen

French National Health Insurance Database (SNDS)clinical coursedisease controldisease severityintensive caremyasthenia gravistreatment

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Reference Centre for Neuromuscular Disease and ALS, Timone University Hospital, Aix-Marseille University, CHU Timone, Filnemus, Euro-NMD, Marseille, France.
  • Department of Neurology, Neuromuscular Disease Reference Centre, Hôpital Nord, University Hospital of Saint-Étienne, Saint-Étienne, France.
  • Department of Neurology, APHP, CHU de Bicêtre, INSERM U1195, Paris-Saclay University, Paris, France.
  • Argenx France, Paris, France.
  • HEVA, Lyon, France.
  • Neurology and Neuromuscular Diseases Department, Neuromuscular Reference Centre AOC, Pellegrin Hospital, Bordeaux University Hospitals, Bordeaux, France.

ORCID-Profile: Shahram Attarian, Jean-Philippe Camdessanché, Andoni Echaniz-Laguna, Guilhem Solé

Förderung

  • Argenx

Zitieren

APA

Attarian, S., Camdessanché, J. P., Echaniz-Laguna, A., Ciumas, M., Blein, C., Grenier, B., & Solé, G. (2025). Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database. European Journal of Neurology, 32(1). https://doi.org/10.1111/ene.16518

Vancouver

Attarian S, Camdessanché JP, Echaniz-Laguna A, Ciumas M, Blein C, Grenier B, et al. Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database. European Journal of Neurology. 2025;32(1). doi:10.1111/ene.16518

BibTeX
@article{Attarian2025,
  author = {Attarian, Shahram and Camdessanché, Jean-Philippe and Echaniz-Laguna, Andoni and Ciumas, Mariana and Blein, Cécile and Grenier, Benjamin and Solé, Guilhem},
  title = {Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {1},
  doi = {10.1111/ene.16518}
}
Kostenlos starten →